Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Jun 27;61(7):e00449-17.
doi: 10.1128/AAC.00449-17. Print 2017 Jul.

Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections

Madeline King  1 , Emily Heil  2 , Safia Kuriakose  3 , Tiffany Bias  4 , Vanthida Huang  5 , Claudine El-Beyrouty  6 , Dorothy McCoy  7 , Jon Hiles  8 , Lynette Richards  3 , Julianne Gardner  9 , Nicole Harrington  9 , Kenneth Biason  3 , Jason C Gallagher  10
Affiliations
Multicenter Study

Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections

Madeline King et al. Antimicrob Agents Chemother. .

Abstract

Ceftazidime-avibactam is a novel cephalosporin-beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE). We describe a retrospective chart review for 60 patients who received ceftazidime-avibactam for a CRE infection. In-hospital mortality was 32%, 53% of patients had microbiological cure, and 65% had clinical success. In this severely ill population with CRE infections, ceftazidime-avibactam was an appropriate option.

Keywords: antibiotic resistance; beta-lactamases; carbapenemase.

PubMed Disclaimer

References

    1. van Duin D, Kaye KS, Neuner EA, Bonomo RA. 2013. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 75:115–120. doi:10.1016/j.diagmicrobio.2012.11.009. - DOI - PMC - PubMed
    1. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. 2014. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 20:1170–1175. doi:10.3201/eid2007.121004. - DOI - PMC - PubMed
    1. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56:2108–2113. doi:10.1128/AAC.06268-11. - DOI - PMC - PubMed
    1. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. 2013. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68:1183–1192. doi:10.1093/jac/dks523. - DOI - PubMed
    1. Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. 2016. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62:1380–1389. doi:10.1093/cid/ciw133. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources